Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy can make some people feel hungrier than expected, particularly in the first few weeks of treatment or after a dose increase. Clinical trial data from the STEP programme show that appetite suppression with semaglutide 2.4mg is real but not uniform — a minority of participants reported increased hunger during the early titration phase. If Wegovy is making you hungry right now, that experience is documented, recognised, and usually temporary. These are prescription-only medicines, and any persistent change in appetite or treatment response should be discussed with your prescriber rather than managed alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity and measured weight, appetite and quality-of-life outcomes over 68 weeks at 2.4mg weekly semaglutide. On average, participants lost around 15% of body weight. Appetite suppression was one of the key mechanisms, but the trial data also captured individual variation, not everyone felt reduced hunger at every dose level, and some reported no appetite change at lower titration steps.
That variation matters. Semaglutide works through GLP-1 receptors in the gut and the brain's hypothalamus, slowing gastric emptying and signalling fullness after smaller meals. Those signals strengthen as the dose climbs. At 0.25mg or 0.5mg, some people notice almost no appetite change at all. This is normal receptor pharmacology, not a sign the medicine is failing you, and our page on why semaglutide might be making you hungry explains exactly why this happens at different stages of treatment.
There is a common misconception worth addressing: many people start Wegovy expecting hunger to vanish on day one. It rarely does. The titration schedule exists partly to protect your digestive system, and therapeutic appetite suppression typically builds across the first eight to twelve weeks as the dose increases. If you are wondering whether Wegovy can actually make you feel hungrier, the answer is more nuanced than most people expect and depends heavily on where you are in the titration schedule.
A distinct pattern some people notice is hunger returning in the 24 to 48 hours before their next injection. Semaglutide has a half-life of around seven days, meaning plasma concentrations dip towards the end of each weekly cycle. For some, that dip is noticeable as a return of appetite in the final day or two.
This end-of-week hunger is worth tracking and reporting. The NHS semaglutide medicines page confirms that your injection day should stay consistent each week; shifting it slightly (with prescriber guidance) can sometimes help smooth the cycle. Do not change your injection schedule independently, that conversation belongs in a clinical review.
If you're consistently hungry towards the end of each week and your weight loss has stalled, your prescriber may consider whether a dose increase is appropriate, or whether something in your routine is working against the medicine. Our detailed look at the reasons Wegovy makes some people hungry covers that end-of-week pattern and what it usually points to.
Food choices interact directly with how Wegovy affects your appetite. Because semaglutide slows gastric emptying, meals higher in protein and fibre stay with you longer, which amplifies the medicine's own effect. Meals centred on refined carbohydrates digest quickly, often leaving you hungry again within two hours regardless of what the medicine is doing.
Some specific things that tend to help: eating protein at every meal (eggs, fish, legumes, Greek yoghurt), keeping meals moderate in volume rather than skipping them entirely, drinking water steadily through the day rather than in large bursts, and not going more than four to five hours without eating during the day. Skipping meals to save calories can paradoxically spike hunger and trigger nausea in others. For a full evidence-informed guide to eating alongside semaglutide, our page on what to eat on Wegovy covers this in detail.
One practical detail: many people find their hunger is most manageable mid-morning after a protein-led breakfast, and worst in the early evening when energy dips. Structuring meals around those windows rather than eating by the clock alone can make a real difference week to week. These are adjustments to discuss with your clinical team; a dietitian alongside your prescriber gives you the most complete picture.
Most hunger on Wegovy is the ordinary kind, a titration-phase effect or an end-of-week dip that settles with time and a few dietary adjustments. But some scenarios need clinical input sooner rather than later.
Speak to your prescriber if: hunger is increasing rather than stabilising after several weeks at a given dose; you're eating significantly more than before you started treatment; weight is actively climbing despite taking your injections as prescribed; or you're experiencing symptoms alongside hunger, such as nausea, vomiting or stomach pain. Persistent or severe stomach pain that radiates to the back should prompt urgent medical attention given what the MHRA has communicated about pancreatitis risk with GLP-1 medicines.
If you're exploring treatment options more broadly or considering whether semaglutide is still the right choice for you, our treatment overview covers the licensed options available in the UK. For questions about cost, this page on Wegovy pricing in the UK explains what to expect from a private prescription. And if you'd like a prescriber to review how your treatment is going, starting a free consultation with our clinical team is the straightforward next step, a real prescriber reads your answers the same day, not software.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.